The Swiss biotech ADC Therapeutics SARL will use an additional $105m of funding it has just raised in a private placement to support the development of two antibody-drug conjugate products it has in Phase I clinical studies that are already producing initial signs of efficacy, and other early-stage pipeline products.
Although antibody-drug conjugate drugs have not attracted the sort of attention lavished on the immune-oncology sector, the new funding round...





